4.5 Review

CD8+ T cells in Trypanosoma cruzi infection

Journal

SEMINARS IN IMMUNOPATHOLOGY
Volume 37, Issue 3, Pages 233-238

Publisher

SPRINGER HEIDELBERG
DOI: 10.1007/s00281-015-0481-9

Keywords

CD8(+) T cells; Trypanosoma cruzi; Chagas disease; Immunodominance; PAMPs; DAMPs

Funding

  1. U.S. National Institutes of Health
  2. Wellcome Trust Foundation
  3. University of Georgia Athletic Association

Ask authors/readers for more resources

Trypanosoma cruzi infection and Chagas disease remains among the most neglected of the neglected tropical diseases. Despite this, studies of the immune response to T. cruzi have provided new insights in immunology and guidance for approaches for prevention and treatment of the disease. T. cruzi represents one of the very best systems in which to study CD8(+) T cell biology; mice, dogs, and primates (and many other mammals) are all natural hosts for this parasite, the robust T cell responses generated in these hosts can be readily monitored using the full range of cutting edge techniques, and the parasite can be easily modified to express (or not) a variety of tags, reporters, immune enhances, and endogenous or model antigens. The infection in most hosts is characterized by vigorous and largely effective immune responses, including CD8(+) T cells capable of controlling T. cruzi at the level of the infected host cells. However, this immune control is only partially effective and most hosts maintain a low level infection for life. This review addresses the interplay of highly effective CD8(+) T cell responses with elaborate pathogen immune evasion mechanisms, including the generation and simultaneous expression of highly variant CD8(+) T cell targets and a host cell invasion mechanisms that largely eludes innate immune detection.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Biotechnology & Applied Microbiology

Recombination-driven generation of the largest pathogen repository of antigen variants in the protozoan Trypanosoma cruzi

D. Brent Weatherly, Duo Peng, Rick L. Tarleton

BMC GENOMICS (2016)

Correction Biochemistry & Molecular Biology

Epigenetic Regulation of Transcription and Virulence in Trypanosoma cruzi by O-Linked Thymine Glucosylation of DNA (vol 31, pg 1690, 2011)

Dilrukshi K. Ekanayake, Todd Minning, Brent Weatherly, Kapila Gunasekera, Daniel Nilsson, Rick Tarleton, Torsten Ochsenreiter, Robert Sabatini

MOLECULAR AND CELLULAR BIOLOGY (2017)

Article Immunology

The Significance of Discordant Serology in Chagas Disease: Enhanced T-Cell Immunity to Trypanosoma cruzi in Serodiscordant Subjects.

Melisa D. Castro Eiro, Maria G. Alvarez, Gretchen Cooley, Rodolfo J. Viotti, Graciela L. Bertocchi, Bruno Lococo, Maria C. Albareda, Ana M. De Rissio, Mar-A A. Natale, Cecilia Parodi, Rick L. Tarleton, Susana A. Laucella

FRONTIERS IN IMMUNOLOGY (2017)

Article Biology

Spontaneous dormancy protects Trypanosoma cruzi during extended drug exposure

Fernando J. Sanchez-Valdez, Angel Padilla, Wei Wang, Dylan Orr, Rick L. Tarleton

ELIFE (2018)

Article Immunology

Distinct Treatment Outcomes of Antiparasitic Therapy in Trypanosoma cruzi -Infected Children Is Associated With Early Changes in Cytokines, Chemokines, and T-Cell Phenotypes

Maria C. Albareda, Maria A. Natale, Ana M. De Rissio, Marisa Fernandez, Alicia Serjan, Maria G. Alvarez, Gretchen Cooley, Huifeng Shen, Rodolfo Viotti, Jacqueline Bua, Melisa D. Castro Eiro, Myriam Nunez, Laura E. Fichera, Bruno Lococo, Karenina Scollo, Rick L. Tarleton, Susana A. Laucella

FRONTIERS IN IMMUNOLOGY (2018)

Article Microbiology

Highly competent, non-exhausted CD8+T cells continue to tightly control pathogen load throughout chronic Trypanosoma cruzi infection

Angela D. Pack, Matthew H. Collins, Charles S. Rosenberg, Rick L. Tarleton

PLOS PATHOGENS (2018)

Review Microbiology

Protozoan persister-like cells and drug treatment failure

Michael P. Barrett, Dennis E. Kyle, L. David Sibley, Joshua B. Radke, Rick L. Tarleton

NATURE REVIEWS MICROBIOLOGY (2019)

Article Microbiology

Strain-specific genome evolution in Trypanosoma cruzi, the agent of Chagas disease

Wei Wang, Duo Peng, Rodrigo P. Baptista, Yiran Li, Jessica C. Kissinger, Rick L. Tarleton

Summary: The protozoan Trypanosoma cruzi establishes life-long infections in humans and other mammals due to the genetic diversity in genes encoding target antigens, which allows the parasite to evade immune responses. This diversity is maintained through processes like gene amplification and recombination, leading to extreme genome flexibility. This poses challenges for developing protective vaccines and contributes to the species-specific biological diversity of T. cruzi.

PLOS PATHOGENS (2021)

Article Infectious Diseases

High variation in immune responses and parasite phenotypes in naturally acquired Trypanosoma cruzi infection in a captive non-human primate breeding colony in Texas, USA

Angel M. Padilla, Phil Y. Yao, Tre J. Landry, Gretchen M. Cooley, Susan M. Mahaney, Isabela Ribeiro, John L. VandeBerg, Rick L. Tarleton

Summary: The study demonstrates the complexity of infection dynamics, parasite phenotypes, and immune response patterns that can occur in a primate group, despite being housed in a uniform environment at a single location, and the limited time period over which the T. cruzi infections were established.

PLOS NEGLECTED TROPICAL DISEASES (2021)

Article Immunology

Avoiding Clinical Trial Failures in Neglected Tropical Diseases: The Example of Chagas Disease

Rick L. Tarleton

Summary: Human clinical trials are costly and failures can discourage future attempts. Chagas disease drug discovery efforts have faced numerous trial failures. Guidelines specific to Chagas disease and other neglected tropical diseases can help avoid these failures by addressing challenges and utilizing advantages such as multi-species natural infection systems.

CLINICAL INFECTIOUS DISEASES (2023)

Article Immunology

Epitopes in the Glycosylphosphatidylinositol Attachment Signal Peptide of Trypanosoma cruzi Mucin Proteins Generate Robust but Delayed and Nonprotective CD8+T Cell Responses

Molly E. Bunkofske, Natasha Perumal, Brooke White, Eva-Maria Strauch, Rick Tarleton

Summary: Infection with Trypanosoma cruzi induces CD8+ T cell responses targeting epitopes in the large trans-sialidase (TS) gene family, but these responses are not essential for immune control. A screen for alternative CD8+ T cell targets identified a previously uncharacterized epitope, MUCKb25, within mucin family proteins. However, the MUCKb25-specific response was dispensable for infection control and vaccination to generate MUCK-specific CD8+ T cells failed to confer protection. These findings highlight the limited effector potential of CD8+ T cells in T. cruzi-infected mice. Journal of Immunology, 2023, 210: 420-430.

JOURNAL OF IMMUNOLOGY (2023)

Article Microbiology

Frequency Variation and Dose Modification of Benznidazole Administration for the Treatment of Trypanosoma cruzi Infection in Mice, Dogs, and Nonhuman Primates

Juan M. Bustamante, Brooke E. White, Gregory K. Wilkerson, Carolyn L. Hodo, Lisa D. Auckland, Wei Wang, Stephanie McCain, Sarah A. Hamer, Ashley B. Saunders, Rick L. Tarleton

Summary: This study demonstrates that higher dose, intermittent administration of benznidazole can effectively treat Trypanosoma cruzi infection. Administration twice a week, for more than 4 months, provides the best chance for parasitological cure.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2023)

Editorial Material Parasitology

Effective drug discovery in Chagas disease

Rick L. Tarleton

Summary: The author and his colleagues have recently reported on a benzoxaborole compound that can consistently cure parasites in experimentally infected mice and naturally infected non-human primates (NHPs). Although these results do not guarantee success in human clinical trials, they significantly reduce the risks and provide strong justification for such trials. Effective drug discovery relies on understanding host and parasite biology and expertise in designing and validating chemical entities. This opinion piece aims to provide insights into the process that led to the discovery of AN15368, hoping to facilitate the discovery of more clinical candidates for Chagas disease.

TRENDS IN PARASITOLOGY (2023)

Article Cell Biology

A modified drug regimen clears active and dormant trypanosomes in mouse models of Chagas disease

Juan M. Bustamante, Fernando Sanchez-Valdez, Angel M. Padilla, Brooke White, Wei Wang, Rick L. Tarleton

SCIENCE TRANSLATIONAL MEDICINE (2020)

No Data Available